Kornimate/medical-research-clean huggingface dataset:
physiotherapy in patients hospitalized due to pneumonia.

Conditions: Pneumonia

Summary: acute respiratory infections are the fourth cause of hospitalization in elderly. various studies have examined the impact of hospitalization in patients with respiratory pathology, showing the need of interventions in order to reduce the impact of hospitalization. the objective of this study is to examine whether a physical therapy intervention can reduce impairment in patients hospitalized due to pneumonia.

acute respiratory infections are the fourth cause of hospitalization in elderly. hospital admissions due to pneumonia range from the 1.1 and 4 per 1,000 patients, increasing with age. hospitalization causes a decline in physical and functional status. physical impairment involves a higher risk of disability and mortality in elderly people. various studies have examined the impact of hospitalization in patients with respiratory pathology, and it has been shown that hospitalization implies a significant physical impairment in patients admitted for pneumonia showing that this deterioration increases with age. that highlights the need of interventions in order to reduce the impact of hospitalization. the objective of this study is to examine whether a physical therapy intervention can reduce impairment in patients hospitalized due to pneumonia.

Eligibility criteria:
inclusion criteria: * diagnosis of pneumonia. * no contraindication of physiotherapy. * signed written consent. * medical approval for inclusion. exclusion criteria: * contraindications of physiotherapy. * neurological, orthopedic or heart disease. * prosthetic devices in lower limbs.

Keywords: pneumonia exacerbation physiotherapy hospitalization
a mail and video-based weight loss trial in breast cancer survivors

Conditions: Breast Cancer Survivorship; Obesity

Summary: proposed is a 6-month randomized controlled trial, in 200 overweight or obese stage i-iiic breast cancer survivors examining 6-month changes in: 1) body weight, 2) diet, 3) physical activity, and 4)quality of life in women randomized to receive the modified lean intervention compared to women randomized to wait-list control (i.e., the wait-list control will receive the modified lean intervention after completing the 6-month study).

the purpose of the study is to evaluate the effects of modifying the lean intervention (nct02110641) to make it more cost effective by reducing or eliminating the counseling sessions. to guide the modification of the intervention one or more focus group sessions with former lean participants will be conducted. the purpose of these meetings will be to gain input on enhancing the lean book. the lean book will be central to the modified intervention, but the lean book will be modified based on feedback from the focus group(s) and experience gained from the lean study. the reading level of the lean book will also be assessed to ensure acceptability to those with a low literacy level. once these changes have been finalized, the efficacy of the modified program will be tested using the methods described in the brief summary.

Eligibility criteria:
inclusion criteria: * overweight individuals (bmi \>= 25.0 kg/m2) * breast cancer survivors who have completed chemotherapy and/or radiation therapy * stage 0-iii * the ability to be physically able to exercise (e.g. walk at a moderate pace) * agree to random assignment to either group * give informed consent to participate in all study activities * accessible by telephone * able read and communicate in english exclusion criteria: * pregnant or intending to become pregnant in the next year * recent (past 6 months) stroke or myocardial infarction * severe uncontrolled mental illness
the exploration of 18f-psma-1007 pet/ct imaging in prostate cancer patients

Conditions: Prostate Cancer

Summary: micro-pet imaging showed that 18f-psma-1007 had similar or even better pharmacokinetics and imaging performance than 18f-dcfpyl. due to the convenience of synthesis and good imaging performance, 18f-psma-1007 is expected to be popularized in clinical practice.the purpose of this study is to evaluate the performance of 18f-psma-1007 in diagnosis, differential diagnosis and efficacy monitoring of prostate cancer.

1. visual analysis of images: describe the location, size, shape and degree of uptake of lesions; 2. semi-quantitative analysis: the ratio of lesion site uptake to liver uptake was measured by area of interest method (roi); 3. comparative analysis: compared with clinical routine 18f-fdg pet/ct imaging, the advantages of psma pet/ct imaging were clarified; 4. evaluation and analysis of efficacy: before and after treatment, to clarify the early treatment evaluation value of psma pet/ct imaging, and compare it with 18f-fdg pet/ct imaging; 5. prognostic study: through multi-factor analysis, the relationship between the level of psma pet/ct imaging uptake and the prognosis of patients was clarified.

Eligibility criteria:
inclusion criteria: prostate cancer is clinically suspected. the patient was diagnosed with prostate cancer by biopsy. prostate cancer needs to be evaluated after treatment. exclusion criteria: patients who did not meet the requirements as assessed by the investigator.

Keywords: prostate cancer pet/ct psma-1007 18f
effect of platelet-rich fibrin on soft tissue, periodontal pocket healing and alveolar bone height after third molar surgery

Conditions: Platelet-rich Fibrin

Summary: a randomized, controlled clinical trial and split-mouth design was performed to assess and compare the effect of platelet-rich fibrin (prf) on soft tissue healing, periodontal pocket depth and alveolar bone height distal to second molar of the study and control groups after third molar surgical removal. sample include of participants who had indication of impacted lower third molars extraction on both sides with symmetrically orientation and same difficult index. all participants had same extraction protocol on both side at department of oral surgery, faculty of odonto-stomatology, university of medicine and pharmacy, ho chi minh city. soft tissue healing, periodontal pocket depth and distal bone height were evaluation by an independent investigator.


Eligibility criteria:
inclusion criteria: * patient over 18 years old. * good general health. * bilateral lower third molars equivalent in inclination and pell and gregory's impaction classification (classification ii, iii and b, c). the assessment of equivalence between two mandibular third molars was determined on the panoramic radiograph. * the difference of third molar inclination on both sides not greater than 15 degrees. * the patient consented to participate in the study after hearing clearly the explanation of purposes and requirements of the study. exclusion criteria: * patients with any systemic disease contraindicated for surgery. * presence of acute inflammation or infection at third molar areas. * patients refused to participate in the study, did not comply with treatment or did not come to the follow-up examination as required. * the difference in surgical time between the two groups was more than 10 minutes.
treatment of mild gestational diabetes with glyburide versus placebo

Conditions: Mild Gestational Diabetes

Summary: this is a randomized prospective trial which addresses the question of whether use of an oral hypoglycemic agent as an adjunct to diet therapy in women with mild gestational diabetes will result in achieving euglycemia in a shorter period of time and, in turn, result in less frequent maternal and neonatal morbidities. this study is designed to test the hypothesis that in women with mild gdm, use of glyburide in addition to diet and nutritional counseling lowers mean infant birth weight by 200 grams as compared with diet and nutritional counseling alone.


Eligibility criteria:
inclusion criteria: * a glucose value of ≥140 mg/dl on a 50-gram oral glucose loading test by plasma at gestational age between 24 weeks 0 days and 27 weeks 6 days based on clinical information * an abnormal 3-hour oral glucose tolerance test with a fasting glucose of ≤105 mg/dl * gestational age of less than or equal to 28 weeks and 0 days at the time of consent/randomization * singleton gestation exclusion criteria: * established pregestational diabetes * abnormal gestational diabetes testing (≥140) prior to 24 weeks 0 days of gestation. women who have a negative glucose loading test (\<140mg/dl) before 24 weeks may still be considered for this study if they present again for glucose tolerance testing between 24 and 27 weeks. * multiple gestations * known major fetal anomaly or fetal demise * any renal disease with serum creatinine of \>1.0 * known liver disease such as hepatitis * maternal or fetal conditions likely to require imminent or very preterm delivery such as preeclampsia, preterm premature rupture of the membranes, preterm labor, and intrauterine fetal growth restriction * known hypersensitivity or allergic reaction to glyburide
randomized trial comparing epiretinal membrane surgery with and without internal limiting membrane removal

Conditions: Epiretinal Membrane

Summary: macular epiretinal membrane (erm) is a semitranslucent, avascular, fibrocellular membrane on the inner surface along the internal limiting membrane (ilm) of the retina. erm may cause symptomatic visual disturbances and vision loss. since the 1970s, pars plana vitrectomy has been performed to remove the membranes with few complications, and surgical results are generally good. recurrence rates of 5-16% have been reported. recently, ilm peeling in erm surgery have been popularized by a number of retrospective studies and one prospective case series to minimize the rate of erm recurrences (16% recurrence in erm surgery with ilm peel compares to 0% recurrence in erm surgery without ilm peel). surgical removal of the friable and transparent ilm is difficult and increases the risk of trauma to the retina. in addition, indocyanine green (icg), a dye commonly used intra-operatively to enhance ilm visualization, is costly and has been shown to be toxic to the retina. the investigators study will be the first randomized-controlled multi-centred clinical trial to compare the outcomes of erm surgery with and without ilm peeling. the results will help guide and standardize the surgical treatment of macular erm; to minimize unnecessary surgical risks, as well as to help economize healthcare cost.


Eligibility criteria:
inclusion criteria: * 18 years or older * erm on clinical exam and/or macular oct * visual acuity of 20/40 or worse (attributable to erm) exclusion criteria: * prior surgery for erm in the "study eye" * macular edema secondary to arterial/venous occlusion(s) * central serous retinopathy * age related macular degeneration * diabetic cystoid macular edema * proliferative diabetic retinopathy * uveitis

Keywords: internal limiting membrane indocyanine green dye
anti-cd33 car-t cells for the treatment of relapsed/refractory cd33+ acute myeloid leukemia

Conditions: Relapsed and/or Refractory Acute Myeloid Leukemia; High Risk Hematologic Malignancies

Summary: this is a phase i, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of anti-cd33 car-t cells in patients with relapsed and/or refractory, high risk hematologic malignancies.

aml is a rapidly progressing blood cancer and treated by high-dose multi-agent chemotherapy potentially followed by hematopoietic stem cell transplantation. despite such intensive therapies, which are often associated with considerable toxicities and even death, about 60-70% of aml patients still relapse. furthermore, the five-year survival rate from aml remains at a dismal 27%. aml is composed mostly of cd33+ leukemic blast cells. therefore, cd33 is a potential good target by car t cells.

Eligibility criteria:
inclusion criteria: 1. signed written informed consent; patients volunteer to participate in the clinical trial; 2. diagnosis is mainly based on the world health organization (who) 2008; 3. complete remission cannot be achieved after induction therapy; recurrence occurs after completion remission; the burden of leukemic blasts in the peripheral blood or bone marrow is greater than 5%; 4. leukemic blast cells express cd33 (cd33 positive by flow cytometry or immunohistochemistry ≥70%); 5. the expected survival period is greater than 12 weeks; 6. ecog score ≤2; 7. age 2-60 years old; 8. hgb≥70g/l (can be transfused); 9. total bilirubin does not exceed 3 times the upper limit of normal value, and ast and alt do not exceed 5 times the upper limit of normal value. exclusion criteria: 1. patients declining to consent for treatment 2. prior solid organ transplantation 3. one of the following cardiac issues: atrial fibrillation; myocardial infarction within the past 12 months; prolonged qt syndrome or secondary qt prolongation; clinically significant pericardial effusion; cardiac insufficiency nyha (new york heart association) iii or iv; 4. history of severe pulmonary dysfunction diseases; 5. severe infection or persistent infection cannot be effectively controlled; 6. severe autoimmune disease or congenital immunodeficiency; 7. active hepatitis; 8. human immunodeficiency virus (hiv) infection; 9. clinically significant viral infections, or uncontrollable viral reactivation, including ebv (epstein-barr virus).

Keywords: cd33 anti-cd33 car leukemia acute myeloid leukemia hematologic malignancies
effects of hyperglycemia on myocardial perfusion in humans with and without type 2 diabetes

Conditions: Coronary Artery Disease; Diabetes Mellitus Type 2

Summary: the overall goal of this proposal is to determine the effects of acute hyperglycemia and its modulation by glucagon-like peptide-1 (glp-1) on myocardial perfusion in type 2 diabetes (dm). this study plan utilizes myocardial contrast echocardiography (mce) to explore a) the effects of acute hyperglycemia on myocardial perfusion and coronary flow reserve in individuals with and without dm; and b) the effects of glp-1 on myocardial perfusion and coronary flow reserve during euglycemia and hyperglycemia in dm. the investigators will recruit individuals with and without dm matched for age, gender and degree of obesity. the investigators will measure myocardial perfusion at rest and during vasodilator stress (to ascertain coronary flow reserve) while subjects are under controlled pancreatic clamp conditions during euglycemia (glucose \~100 mg/dl) and hyperglycemia (glucose \~250 mg/dl) in the presence and absence of concomitant glp-1 infusion. the investigators believe that the translational significance of their studies is immense, impacting upon both acute and chronic cardiovascular disease manifestations. the effect of glycemic control on cardiovascular outcomes, morbidity and mortality remains an area of active investigation, fueled by the recent conflicting results of several large clinical trials (accord, united kingdom prospective diabetes study (ukpds), advance, vadt). if the investigators find that hyperglycemia is associated with altered myocardial perfusion, the mechanistic implications in the prevention and management of acute and chronic cardiovascular diseases in dm will be groundbreaking. furthermore, if glp-1 augments myocardial perfusion (as it does in the peripheral vasculature), the therapeutic benefits for prevention of cardiovascular events in this predisposed population are clear.


Eligibility criteria:
inclusion criteria: * males and females * age 40-60 years * bmi\< or = 35 kg/m2 * diabetic subjects with hba1c concentrations of \< or = 8%. * diabetic subjects will be either on diet and lifestyle therapy alone, or monotherapy with metformin or sulphonylureas (except glyburide). * all diabetic subjects should be on stable dose oral agent therapy for 3 months prior to enrollment. exclusion criteria: * subjects with cerebrovascular or peripheral vascular disease. * subjects with suspected or overt autonomic neuropathy. * diabetic subject on thiazolidinediones, insulin, glp-1 based therapies (exenatide or sitagliptin), alpha-glucosidase inhibitors, glyburide or combination antidiabetic drug therapies. * diabetics with microalbuminuria.

Keywords: glp-1 myocardial contrast echocardiography myocardial perfusion
prospective multicentre study assessing the feasibility of enhanced recovery after sleeve gastrectomy for obesity

Conditions: Obesity

Summary: the primary purpose of the study is to test the feasibility of a protocol of enhanced recovery after surgery for reducing the total length of hospital stay in a large scale setting

this observational study evaluates the feasibility of eras pathway in six french departments of surgery located at clermont-ferrand, bordeaux, montpellier, amiens, strasbourg and aurillac.

Eligibility criteria:
inclusion criteria: * obese patients undergoing a sleeve gastrectomy patients having signed the informed consent patients over 18 year old asa 1-3 obesity with indication for surgery according the guidelines of the french high authority for health bmi \< 50 kg/m2 no contra-indication for general anesthésia exclusion criteria: contra-indication for general anesthésia age under 18 years asa 4 bmi \> 50 kg/m2 patients having other serious comorbidities: cardiac, pulmonary, diabete, immunodepression, coagulopathy ou anticoagulant therapy pregnancy patients living alone

Keywords: enhanced recovery, sleeve gastrectomy,
the efficacy of open label infliximab for the induction and maintenance of mucosal healing in small bowel crohn's disease assessed through wireless camera endoscopy

Conditions: Crohn's Disease

Summary: this is a pilot study to estimate the efficacy of infliximab in inducing and maintaining healing of lesions in the mucosa of subjects with crohn's disease involving their small bowel.

landmark trials in crohn's disease demonstrated the efficacy of infliximab in inducing and maintaining clinical remission. furthermore, the endoscopic sub-studies within these trials demonstrated the ability of infliximab to rapidly induce and maintain mucosal healing as evidenced by the complete absence of mucosal breaks in the colon and terminal ileum. unfortunately, conventional colonoscopy does not allow intestinal exploration beyond a very restricted portion of the small bowel (at most 10-15 cm of the terminal ileum). a study that systematically examines the changes in the small bowel mucosa during crohn's disease symptomatic improvement is clearly needed. this study consists of 20 subjects and 30 weeks of follow up. all subjects will undergo wireless camera endoscopy at three (3) visits, namely: at screening, at week 10 and at week 26. infliximab is administered at (5) visits, namely: at baseline (week 0), week 2, week 6, week 14 and week 22. in some subjects, an ileal-colonoscopy may be performed at week 26.

Eligibility criteria:
inclusion criteria: * 18 years old * established diagnosis of crohn's disease and evidence of small bowel involvement * cdai score between 220 and 450 inclusively * lewis score of at least 790 at screening * colonoscopy within the last 6 months * successful excretion of the intact patency capsule exclusion criteria * contraindications to anti-tnf therapy (tb, cardiac impairment, etc.) * prior bowel resection * prior anti-tnf exposure

Keywords: crohn's disease infliximab capsule endoscopy
stereotactic laser ablation for temporal lobe epilepsy (slate)

Conditions: Temporal Lobe Epilepsy

Summary: the study is designed to evaluate the safety and efficacy of the visualase mri-guided laser ablation system for mesial temporal epilepsy (mtle).

the purpose of the study is to evaluate the safety and efficacy of the visualase mri-guided laser ablation system for necrotization or coagulation of epileptogenic foci in patients with intractable mesial temporal lobe epilepsy. the study will include approximately 150 adult patients with drug-resistant mtle treated at selected epilepsy centers across the united states. after the visualase procedure, patients will be followed for 12 months and evaluated for freedom from seizures, quality of life, adverse events, and neuropsychological outcomes.

Eligibility criteria:
inclusion criteria: * history of drug-resistant mesial temporal lobe epilepsy (mtle) * if the subject has a vagus nerve stimulator (vns), must have failed to achieve sustained seizure freedom with the vns implanted for at least 6 months * on stable antiepileptic drugs (aeds) (and/or stable vns setting, if applicable) and compliant with medication use * an average of at least 1 complex partial or secondarily generalized seizure compatible with mtle per month * seizure symptoms and/or auras compatible with mtle * video eeg shows evidence of seizures from one temporal lobe consistent with mtle * mri has evidence consistent with mesial temporal lobe sclerosis * willing and able to remain on stable aeds (and stable vns setting, if applicable) for 12 months following the visualase procedure * willing and able to comply with protocol requirements * able to complete study assessments in english or spanish language exclusion criteria: * unwilling or unable to sign the study informed consent form * pregnant or intends to become pregnant during the course of the study * currently implanted with a device contraindicating mri * progressive brain lesions and/or tumors not associated with epileptic disease state * history of previous intracranial surgery for treatment of epileptic seizures * persistent extra-temporal or predominant contralateral focal interictal spikes or slowing, or generalized interictal spikes on eeg * seizures with contralateral or extra-temporal ictal onset on eeg * aura and/or ictal behavior suggest an extra-temporal focus * mri evidence of epileptogenic, extra-temporal lesions, dual pathology in the temporal lobe, or contralateral hippocampal mri increased signal and/or loss of architecture * if additional testing has been performed, results are discordant with the seizure focus scheduled for ablation * non-compliance with aed requirements * iq \< 70 * dementia or other progressive neurological disease * unstable major psychiatric illness, psychogenic non-epileptic seizures, or medical illness that would contraindicate the visualase procedure or affect the neuropsychological assessments * participation in other research that may potentially interfere with slate endpoint(s) * allergy to gadolinium

Keywords: epilepsy laser ablation visualase laser interstitial thermal therapy
using radiation-free ultrasound for screening scoliosis among school children in hong kong to reduce unnecessary x-ray exposure

Conditions: Scoliosis

Summary: in the scoliosis screening program of the student health service (shs), department of health (dh), in hong kong, more than 50% of screened school children prescribed with x-ray examination basing on the screening protocol did not have cobb angle greater than the referral threshold of 20°; ie they did not need specialist referral and thus were subjected to unnecessary x-ray exposure. our primary objective is to determine whether a new radiation-free ultrasound system could identify subjects with cobb angle greater than the referral threshold of 20° thus avoiding unnecessary x-rays in the referral workflow. the secondary objective is to evaluate if angle of trunk rotation (atr) can further increase the accuracy of ultrasound assessment.


Eligibility criteria:
inclusion criteria: i. schoolchildren in hong kong attending school screening program provided by student health service ii. recommended for radiographic assessment in the scoliosis screening program exclusion criteria: * i. patients with standing height \ 2 m ii. patients with body mass index (bmi) ≥25 kg/m2 iii. subjects with skin diseases iv. subjects with fracture or wound that affect ultrasound scanning v. subjects with ferromagnetic implants vi. subjects with surgery done for the spine vii. subjects with winged scapula or other irregularity of back contour that affect ultrasound scanning viii. subjects who cannot stand steadily during scanning ix. subjects with allergy to ultrasound gel